Rex Health Ventures

410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously. This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited. It was founded in 2013 and headquartered in Durham, North Carolina.

G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, specializing in the manufacture of medical devices that utilize surgical anastomotic technology. Founded in 2012, the company aims to revolutionize surgical procedures by developing less invasive techniques for treating obesity and type 2 diabetes. G.I. Windows is focused on creating innovative solutions that not only enhance patient outcomes but also contribute to cost reduction in the healthcare system. Through its commitment to advancing surgical technology, the company seeks to establish a new category in healthcare, enabling the development of procedures that are novel and less invasive.

Synaptrix is committed to offering free of drugs, lasting alternatives for postoperative pain treatment using NOVABLOC.

Arrivo BioVentures LLC is a biopharmaceutical company based in Morrisville, North Carolina, established in 2015. The company specializes in the development of biologics and small molecules aimed at enhancing patient care. Arrivo BioVentures focuses on reformulating existing drugs and creating new chemical entities, employing its expertise to navigate regulatory strategies that streamline the approval process. By collaborating closely with regulatory bodies such as the FDA, the company aims to minimize unexpected challenges and accelerate the implementation of its clinical programs. Through its innovative approach, Arrivo BioVentures seeks to meet the demands of the biotechnology sector while prioritizing the improvement of patient outcomes.

Censinet, Inc. is a healthcare-focused SaaS company that offers a cloud-based platform for managing third-party risk assessments. Founded in 2017 and based in Winchester, Massachusetts, Censinet connects healthcare providers with their vendors, streamlining the process of assessing and managing risks in real time. The platform eliminates the need for inefficient spreadsheets and manual workflows by automating risk assessments and providing continuous insights into vendor profiles. This approach enables healthcare organizations to identify and address potential threats within their vendor ecosystem effectively, enhancing overall cybersecurity and operational efficiency.

Vergent Bioscience, Inc. specializes in developing tumor-targeted fluorescent probes that enhance the surgical removal of cancerous tissue. Founded in 2013 and based in Minneapolis, Minnesota, the company’s flagship product, VGT-309, is a molecularly-targeted imaging molecule designed to bind to enzymes overexpressed in various tumor tissues. Upon injection before surgery, VGT-309 activates a brightly fluorescing dye, enabling surgeons to visually distinguish cancerous tissue from normal tissue during procedures. This technology aims to improve surgical outcomes by ensuring the complete removal of tumors, which is crucial for increasing cure rates. Vergent Bioscience's innovative approach addresses a significant clinical need for advanced visualization in various surgical settings, including open, laparoscopic, and robotic surgeries.

Pryon Inc. is an artificial intelligence company based in Raleigh, North Carolina, that focuses on enhancing enterprise knowledge management. Founded in 2017 by Igor Jablokov, Pryon develops an augmented intelligence platform that combines human and machine capabilities to streamline access to information across various channels and sources. The platform employs natural language processing and automated machine learning to transform unstructured data into actionable insights, thereby boosting productivity and decision-making accuracy. By utilizing a no-code approach, Pryon enables organizations to quickly harness the value of their information assets without disrupting existing operations. The company's solutions aim to simplify AI adoption, reduce complexity, and lower costs for businesses seeking to improve their workflows and knowledge utilization.

BioStable Science & Engineering, Inc. is a cardiovascular device company based in Austin, Texas, that specializes in developing valve repair technologies as alternatives to valve replacement for patients with aortic valve disease. The company offers a range of HAART aortic valve repair technologies, including the HAART 300 aortic annuloplasty device, designed to reduce annular dilatation and restore three-dimensional annular geometry, and the HAART 200 device tailored for bicuspid aortic valve repair. Additionally, BioStable's aortic root restoration system aims to enhance surgical outcomes for patients with aortic insufficiency or aortic root aneurysm. Founded in 2008, BioStable leverages its expertise in product development, regulatory affairs, and clinical validation to minimize time to market for its innovative medical devices, ultimately improving patient care in the cardiovascular field.

Bardy Diagnostics is a developer of a cardiac monitor and arrhythmia detection device. The company has created a new, state-of-the-art heart monitor known as Carnation Ambulatory Monitor (CAM) that can be worn comfortably and discreetly for up to 7 days. Unlike many other heart monitors, CAM can be worn during exercise or while showering. Its unique, narrow, hourglass shape makes it especially advantageous for the female anatomy. It is also designed to be comfortable for women to wear, with its narrow, hourglass shape. Bardy Diagnostics uses his expertise to develop cardiac monitoring solutions that help physicians obtain more accurate information about actionable events in the hopes of saving lives. The company's mission is to improve clinical management and outcomes for patients and their physicians by employing innovative P-wave centric ECG detection into patient-friendly technologies that result in greater patient compliance and more confident physician diagnoses. Bardy Diagnostics was founded in 2013 and is headquartered in Seattle, Washington, USA.

Phynd Technologies Inc. operates a Software-as-a-Service data management platform designed to streamline healthcare provider data management for healthcare organizations in the United States. The company's Unified Provider Management (UPM) platform centralizes critical provider data, enabling organizations to effectively gather, manage, and share information across various IT systems. This enhances financial performance and clinical outcomes while minimizing compliance risks. Key features of the platform include tools for managing billing addresses, communication preferences, licensing, and provider enrollment in real-time. Phynd's services are utilized by over 350 hospitals and more than 20,000 locations across the country, allowing these entities to maintain a comprehensive hub of provider data for applications in electronic health records, marketing, and claims systems. Founded in 2012 and headquartered in Dallas, Texas, Phynd Technologies has established partnerships to further enhance its service offerings.

Gauss Surgical, Inc. specializes in real-time blood monitoring solutions that enhance clinical decision-making in the healthcare sector. The company has developed a vision-based platform that provides accurate estimations of blood loss, facilitating timely transfusion decisions and improving patient outcomes. Its flagship product, Triton, is utilized in obstetrics to aid in the early detection of postpartum hemorrhage and offers objective metrics for assessing blood loss. Additionally, Gauss Surgical offers Triton OR, designed for operating rooms to measure blood loss from surgical sponges and suction canisters, and Triton L&D, which focuses on vaginal delivery and postpartum care. Founded in 2011, Gauss Surgical operates from its headquarters in Menlo Park, California.

Emergo Therapeutics is a pharmaceutical startup that develops treatment options for flu-like illnesses. It is focused on developing drugs to modulate inflammatory cytokines and improve the functioning of the immune system in various potential indications, starting with infectious diseases. Emergo’s therapeutic interventions are focused on reducing the production of inflammatory cytokines from mast cells. Emergo is headquartered in Durham, North Carolina.

TARGET PharmaSolutions, Inc. specializes in providing real-world data solutions to enhance drug development and commercialization processes. Established in 2015 in Durham, North Carolina, the company focuses on creating custom datasets and analyses to address complex healthcare evidence questions. TARGET PharmaSolutions offers comprehensive health evidence solutions that aggregate real-world data from a network of participating sites, alongside bio specimen samples and consulting services. The company emerged from the success of HCV-TARGET, a model developed for Hepatitis C that has garnered significant investment and involvement from the FDA. This background has positioned TARGET PharmaSolutions to effectively support sponsors in expanding product labels and reducing the need for costly Phase IV studies.

Phononic is a growth stage, semiconductor hardware company commercializing solid-state heat pumps and fully integrated systems that displace compressors, heat sinks, and fans for electronics cooling; residential and commercial refrigeration; and climate control. The company’s disruptive approach combines high-performance solid-state heat pumps integrated into a manufacturing-friendly systems architecture that realizes products that are smart, sustainable, and solid state-driven.

Bluesight addresses supply chain inefficiencies in healthcare by offering actionable analytics throughout the medication lifecycle. The company has developed a hospital inventory management platform that automates pharmacy kit processing and medication tracking, aiming to streamline the often cumbersome and error-prone manual processes associated with medication handling. By implementing automation technology, Bluesight enhances operational efficiency, improves patient safety, and increases medication visibility within hospitals. Through its suite of Medication Intelligence solutions, the company simplifies the complexities of medication management, providing healthcare professionals with the tools needed for better decision-making and risk reduction.

Arrivo BioVentures LLC is a biopharmaceutical company based in Morrisville, North Carolina, established in 2015. The company specializes in the development of biologics and small molecules aimed at enhancing patient care. Arrivo BioVentures focuses on reformulating existing drugs and creating new chemical entities, employing its expertise to navigate regulatory strategies that streamline the approval process. By collaborating closely with regulatory bodies such as the FDA, the company aims to minimize unexpected challenges and accelerate the implementation of its clinical programs. Through its innovative approach, Arrivo BioVentures seeks to meet the demands of the biotechnology sector while prioritizing the improvement of patient outcomes.

Veran Medical Technologies is a medical device company focused on developing minimally invasive solutions for interventional oncology procedures. Based in St. Louis, Missouri, the company offers a range of products, including the SPiNView thoracic navigation system, which aids physicians in performing biopsies on solitary pulmonary nodules for early lung cancer diagnosis. Other key offerings include the ig4 IR System, a platform that assists in biopsies and ablations for various organs, and the SPiNPerc device for hybrid diagnostic procedures. The company also provides vPad2, a tracking device for instrument positioning during surgery, and the vTrack 2.0 Instruments, which guide physicians to peripheral lung regions. Veran's technology enhances diagnostic accuracy and therapy delivery by integrating various imaging modalities, ultimately aiming to improve patient outcomes through earlier cancer detection and treatment.

Baebies, Inc. is a company based in Durham, North Carolina, that specializes in manufacturing screening and pediatric testing equipment for newborns. Founded in 2014 by Richard West and Vamsee Pamula, Baebies developed its newborn screening platform, SEEKER, which is FDA authorized and CE marked. SEEKER enables the simultaneous performance of multiple assays to quantitatively measure the activity of lysosomal enzymes from a single dried blood spot specimen. Additionally, the company produces the FINDER near-patient testing equipment, which also holds CE marking, and the FINDER 1.5 platform, which includes a SARS-CoV-2 test with emergency use notification from the FDA. Baebies utilizes digital microfluidics technology, allowing for efficient diagnostics from low-volume samples, and aims to enhance early disease detection for both children and adults. The company serves hospitals and public health labs, focusing on improving newborn health outcomes and providing innovative diagnostic solutions.

Bluesight addresses supply chain inefficiencies in healthcare by offering actionable analytics throughout the medication lifecycle. The company has developed a hospital inventory management platform that automates pharmacy kit processing and medication tracking, aiming to streamline the often cumbersome and error-prone manual processes associated with medication handling. By implementing automation technology, Bluesight enhances operational efficiency, improves patient safety, and increases medication visibility within hospitals. Through its suite of Medication Intelligence solutions, the company simplifies the complexities of medication management, providing healthcare professionals with the tools needed for better decision-making and risk reduction.

Aerial BioPharma LLC is a biopharmaceutical company based in Morrisville, North Carolina, established in 2011. The company specializes in drug development aimed at addressing conditions related to the central nervous system. Aerial BioPharma focuses on creating both biologics and small molecules, particularly targeting treatments for narcolepsy and other neurological disorders. By advancing innovative therapies, the company aims to enhance treatment options available to healthcare institutions and improve patient outcomes in the realm of central nervous system disorders.